Literature DB >> 1954386

Expression of L-myc and N-myc proto-oncogenes in human leukemias and leukemia cell lines.

H Hirvonen1, V Hukkanen, T T Salmi, T P Mäkelä, T T Pelliniemi, S Knuutila, R Alitalo.   

Abstract

The myc proto-oncogenes encode nuclear phosphoproteins, which are believed to participate in the control of cell proliferation and differentiation. Deregulated expression of c-myc has been implicated in several human hematopoietic malignancies. We have studied the expression and mRNA processing of human L-myc, N-myc, and c-myc genes in a panel of human leukemias, leukemia cell lines, and normal hematopoietic cells. L-myc mRNA was expressed in three acute myeloid leukemias (AML) studied and in several myeloid leukemia cell lines. Only low expression levels were observed in adult bone marrow and in fetal spleen and thymus. The K562 and Dami leukemia cell lines showed a unique pattern of L-myc mRNA processing, with approximately 40% of L-myc mRNA lacking exon III and intron I. N-myc was expressed in five of six AML cases studied, in one of nine acute lymphocytic leukemia (ALL) cases, and in several leukemia cell lines, while c-myc mRNA was detected in all leukemias and leukemia cell lines studied. Coexpression of all three myc genes was observed in Dami and MOLT-4 cell lines and in two AMLs, and either L-myc or N-myc was coexpressed with c-myc in several other cases. These results show that in addition to c-myc, the L-myc and N-myc genes are expressed in some human leukemias and leukemia cell lines, and suggest a lack of mutually exclusive cross-regulation of the myc genes in human leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954386

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.

Authors:  Jianbiao Zhou; Wee-Joo Chng
Journal:  Stem Cell Investig       Date:  2017-02-09

2.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

3.  Co-expression of collagens II and XI and alternative splicing of exon 2 of collagen II in several developing human tissues.

Authors:  M M Sandberg; H E Hirvonen; K J Elima; E I Vuorio
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

4.  Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis.

Authors:  Yu Fukuda; Yao Wang; Shangli Lian; John Lynch; Shinjiro Nagai; Bruce Fanshawe; Ayten Kandilci; Laura J Janke; Geoffrey Neale; Yiping Fan; Brian P Sorrentino; Martine F Roussel; Gerard Grosveld; John D Schuetz
Journal:  JCI Insight       Date:  2017-08-03

5.  Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.

Authors:  M Affer; S Dao; C Liu; A B Olshen; Q Mo; A Viale; C L Lambek; T G Marr; B D Clarkson
Journal:  J Oncol       Date:  2011-02-23       Impact factor: 4.375

6.  MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Annalisa Astolfi; Francesca Vendemini; Milena Urbini; Fraia Melchionda; Riccardo Masetti; Monica Franzoni; Virginia Libri; Salvatore Serravalle; Marco Togni; Giuseppina Paone; Luca Montemurro; Daniela Bressanin; Francesca Chiarini; Alberto M Martelli; Roberto Tonelli; Andrea Pession
Journal:  Oncotarget       Date:  2014-01-15

Review 7.  The MYCN Protein in Health and Disease.

Authors:  María Victoria Ruiz-Pérez; Aine Brigette Henley; Marie Arsenian-Henriksson
Journal:  Genes (Basel)       Date:  2017-03-30       Impact factor: 4.096

8.  Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines.

Authors:  H E Hirvonen; R Salonen; M M Sandberg; E Vuorio; I Västrik; E Kotilainen; H Kalimo
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

9.  Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells.

Authors:  Christopher Bryant; Kirsten Scriven; Andrew J Massey
Journal:  Mol Cancer       Date:  2014-06-10       Impact factor: 27.401

10.  MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.

Authors:  Li Liu; Feng Xu; Chun-Kang Chang; Qi He; Ling-Yun Wu; Zheng Zhang; Xiao Li
Journal:  Cell Death Dis       Date:  2017-10-12       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.